Biomedical Engineering Reference
In-Depth Information
responses in tumor cells treated with a PARC-interacting
peptide. Biochem. Biophys. Res. Commun. 368, 350-356.
76. Wadia J, Dowdy S. (2005) Transmembrane delivery of pro-
tein and peptide drugs by TAT-mediated transduction in the
treatment of cancer. Adv. Drug Deliv. Rev. 57, 579-596.
77. Wheeler D, Dunsmore K, Wong H. (2003) Intracellular
delivery of HSP70 using HIV-1 Tat protein transduction
domain. Biochem. Biophys. Res. Commun. 301, 54-59.
78. Kameyama S, Horie M, Kikuchi T, Omura T, Tadokoro A,
Takeuchi T, et al. (2007) Acid wash in determining cellular
uptake of fab/cell-permeating peptide conjugates. Biopoly-
mers 88, 98-107.
79. Yu HH, Nakase I, Pujals S, Hirose H, Tanaka G, Katayama S,
et al. (2010) Expressed protein ligation for the preparation of
fusion proteins with cell penetrating peptides for endotoxin
removal and intracellular delivery. Biochim. Biophys. Acta.
1798, 2249-2257.
80. Merrifield RB. (1963) Solid phase peptide synthesis. I. The
synthesis of a tetrapeptide'. J. Am. Chem. Soc. 85, 2149-2154.
81. Planel S, Salomon A, Jalinot P, Feige J, Cherradi N. (2010) A
novel concept in antiangiogenic and antitumoral therapy:
multitarget destabilization of short-lived mRNAs by the
zinc finger protein ZFP36L1. Oncogene. 29(45), 5989-6003.
82. Cuatrecasas P, Wilchek M, Anfinsen C. (1968) Selective
enzyme purification by affinity chromatography. Proc.
Natl. Acad. Sci. USA 61, 636-643.
83. Hochuli E, Bannwarth W, Dobeli H, Gentz R, Stuber D.
(1988) Genetic approach to facilitate purification of recom-
binant proteins with a novel metal chelate adsorbent. Nat.
Biotech. 6, 1321-1325.
84. Gao S, Simon M, Morrison BR, Banta S. (2009) Bifunctional
chimeric fusion proteins engineered for DNA delivery: opti-
mization of the protein to DNA ratio. Biochim. Biophys. Acta.
1790, 198-207.
85. Massodi I, Raucher D. (2007) A thermally responsive Tat-
elastin-like polypeptide fusion protein induces membrane
leakage, apoptosis, and cell death in human breast cancer
cells. J. Drug Target. 15, 611-622.
86. Massodi I, Bidwell GR, Davis A, Tausend A, Credit K,
Flessner M, et al. (2009) Inhibition of ovarian cancer cell
metastasis by a fusion polypeptide Tat-ELP. Clin. Exp.
Metastasis 26, 251-260.
87. Massodi I, Moktan S, Rawat A, Bidwell GR, Raucher D.
(2010) Inhibition of ovarian cancer cell proliferation by a cell
cycle inhibitory peptide fused to a thermally responsive
polypeptide carrier. Int. J. Cancer 126, 533-544.
88. Zender L, Kuhnel F, Kock R, Manns M, Kubicka S. (2002)
VP22-mediated intercellular transport of p53 in hepatoma
cells in vitro and in vivo. Cancer Gene Therapy 9, 489-496.
89. Harris MP, Sutjipto S, Wills K, Hancock W, Cornell D,
Johnson D, et al. (1996) Adenovirus-mediated p53 gene
transfer inhibits growth of human tumor cells expressing
mutant p53 protein. Cancer Gene Therapy 3, 121-130.
90. Fang B, Xu B, Koch P, Roth J. (1998) Intercellular trafficking
of VP22-GFP fusion proteins is not observed in cultured
mammalian cells. Gene Therapy 5, 1420-1424.
91. Zavaglia D, Lin E, Guidetti M, Pluquet O, Hainaut P, Favrot
M, et al. (2005) Poor intercellular transport and absence of
enhanced antiproliferative activity after non-viral gene trans-
fer of VP22-P53 or P53-VP22 fusions into p53 null cell lines
in vitro or in vivo. J. Gene Med. 7, 936-944.
92. Wang H, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang J,
et al. (2002) Induction of CD4(
รพ
) T cell-dependent antitumor
immunity by TAT-mediated tumor antigen delivery into
dendritic cells. J. Clin. Invest. 109, 1463-1470.
93. Kim C, Woo S, Park J, Kim H, Park M, Park S, et al. (2007)
Enhanced antitumour immunity by combined use of temo-
zolomide and TAT-survivin pulsed dendritic cells in a murine
glioma. Immunology 122, 615-622.
94. Rautsi O, Lehmusvaara S, Ketola A, Maatta A, Wahlfors J,
Pellinen R. (2008) Characterization of HIV-1 TAT peptide as
an enhancer of HSV-TK/GCV cancer gene therapy. Cancer
Gene Therapy 15, 303-314.
95. Song H, Lee J, Ju S, Yoo K, Won M, Kwon H, et al. (2008)
Topical transduction of superoxide dismutase mediated by
HIV-1 Tat protein transduction domain ameliorates 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced inflamma-
tion in mice. Biochem. Pharmacol. 75, 1348-1357.
96. Trouba K, Hamadeh H, Amin R, Germolec D. (2002) Oxida-
tive stress and its role in skin disease. Antioxid. Redox Signal.
4, 665-673.
97. Regan E, Flannelly J, Bowler R, Tran K, Nicks M, Carbone
B, et al. (2005) Extracellular superoxide dismutase and
oxidant damage in osteoarthritis. Arthritis Rheum. 52,
3479-3491.
98. Kabouridis P, Hasan M, Newson J, Gilroy D, Lawrence T.
(2002) Inhibition of NF-kappa B activity by a membrane-
transducing mutant of I kappa B alpha. J. Immunol. 169,
2587-2593.
99. Klein D, Ribeiro M, Mendoza V, Jayaraman S, Kenyon N,
Pileggi A, et al. (2004) Delivery of Bcl-XL or its BH4 domain
by protein transduction inhibits apoptosis in human islets.
Biochem. Biophys. Res. Commun. 323, 473-478.
100. Chen X, Lai J, Pan Q, Tang Z, Yu Y, Zang G. (2010) The
delivery of HBcAg via Tat-PTD enhances specific immune
response and inhibits Hepatitis B virus replication in trans-
genic mice. Vaccine 28, 3913-3919.
101. Wang S, Han Q, Zhang N, Chen J, Liu Z, Zhang G, et al.
(2010) HBcAg18-27 epitope fused to HIV-Tat 49-57 adju-
vanted with CpG ODN induces immunotherapeutic effects in
transgenic mice. Immunol. Lett. 127, 143-149.
102. Yi J, Gong W, Wang L, Ling R, Chen J, Yun J. (2005) VP22
fusion protein-based dominant negative mutant can inhibit
hepatitis B virus replication. World J. Gastroenterol. 11,
6429-6432.
103. Kilic E, Kilic U, Hermann D. (2006) TAT fusion proteins
against ischemic stroke: current status and future perspec-
tives. Front. Biosci. 11, 1716-1721.
104. Gou X, Wang Q, Yang Q, Xu L, Xiong L. (2010) TAT-NEP1-
40 as a novel therapeutic candidate for axonal regeneration
and functional recovery after stroke. J. Drug Target. 19(2),
86-95.
Search WWH ::
Custom Search